Status:

UNKNOWN

PROgnostic Value of Exercise Capacity Measured as Peak Oxygen Uptake (pVO2) in Recipients of Left Ventricular Assist Devices

Lead Sponsor:

Rigshospitalet, Denmark

Conditions:

Left Ventricular Assist Device

Prognosis

Eligibility:

All Genders

18+ years

Brief Summary

Pooling of earlier VO2-studies conducted at the dept. of cardiology, Rigshospitalet, Denmark, and all LVAD centres of the World that wish to participate. The purpose is to investigate the prognostic ...

Detailed Description

Background and purpose: Peak oxygen uptake (pVO2) is used extensively in HF to predict prognosis and time for heart transplantation. Many centers are increasingly measuring pVO2 in LVAD supported HF ...

Eligibility Criteria

Inclusion

  • Durable LVAD implantation
  • VO2 in stable post implant phase

Exclusion

  • No VO2 data available
  • Concomittant RVAD (temp/durable device)

Key Trial Info

Start Date :

April 10 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2022

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT04423562

Start Date

April 10 2020

End Date

December 31 2022

Last Update

June 9 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Rigshospitalet

Copenhagen, DK, Denmark, 2100